THMA Oncology Forum 2026: Pharma Insights & Health System Strategy

Key Takeaways

• The THMA Oncology Forum 2026 includes both Spring (Fort Lauderdale) and Fall (Boston) events.
• The forum's primary focus is on fostering engagement between pharmaceutical companies and health systems, with an emphasis on pathway governance and clinical implementation strategies.
• The target audience includes pharmaceutical commercial leaders and oncology market access teams.
• The forum aims to address the challenges posed by the rapid pace of FDA oncology approvals, which often outstrips the capacity of health systems to evaluate and integrate new therapies.

The THMA Oncology Forum 2026 will host two events, one in Fort Lauderdale, FL, from May 6-8, and another in Boston, MA, from September 16-18. These forums are designed to facilitate direct engagement between pharmaceutical companies and oncology decision-makers from leading health systems. The events aim to address key challenges and opportunities in oncology care, with a focus on pathway governance and market trends.

The THMA Oncology Forum is significant because it provides a platform for pharmaceutical companies and health systems to collaborate on strategies for improving oncology care. With the increasing number of new cancer therapies being approved by the FDA, it is crucial for health systems to have effective processes in place for evaluating and implementing these treatments. The forum offers a space for stakeholders to discuss best practices and develop solutions to ensure that patients have access to the most appropriate and effective therapies.

Key discussion points at the THMA Oncology Forum 2026 will include pathway governance and formulary positioning, clinical implementation strategies, and the alignment of health system oncology strategy with fiscal planning. The forum will also feature AI-driven pre-conference sessions and main stage presentations on topics such as pathway governance, prescribing behavior, and precision oncology.

The target audience for the THMA Oncology Forum includes pharmaceutical commercial leaders and market access teams, as well as health system executives from institutions such as Mayo Clinic and Cleveland Clinic. The forum aims to maintain a 1:1 health system-to-industry ratio for closed-door discussions, fostering a collaborative environment for sharing insights and developing solutions.

Given the absence of specific drug or trial data, the focus will be on broader strategic discussions around market access, pathway development, and health system integration. Attendees will likely be interested in understanding how to navigate the evolving landscape of oncology care and ensure that their organizations are well-positioned to deliver high-quality, cost-effective care.

Looking ahead, it will be important to monitor the outcomes of the THMA Oncology Forum and assess its impact on the adoption of new cancer therapies and the improvement of oncology care delivery. Future events may provide more specific data on drug pipelines and clinical trial results, offering further insights into the latest advances in cancer treatment.

Frequently Asked Questions

• What is the THMA Oncology Forum?

  The THMA Oncology Forum is a series of events designed to facilitate collaboration between pharmaceutical companies and health systems in the field of oncology. It focuses on topics such as pathway governance, formulary positioning, and clinical implementation strategies.

• Who is the target audience for the forum?

  The target audience includes pharmaceutical commercial leaders, oncology market access teams, and health system executives from leading institutions.

• Where and when will the THMA Oncology Forum 2026 take place?

  The THMA Oncology Forum 2026 will consist of two events: the Spring Forum in Fort Lauderdale, FL, from May 6-8, 2026, and the Fall Forum in Boston, MA, from September 16-18, 2026.

• What topics will be discussed at the forum?

  Key discussion points will include pathway governance, formulary positioning, clinical implementation strategies, and the alignment of health system oncology strategy with fiscal planning. AI-driven presentations on pathway governance, prescribing behavior, and precision oncology will also be featured.

• What is the significance of the THMA Oncology Forum?

  The forum provides a platform for pharmaceutical companies and health systems to collaborate on strategies for improving oncology care, addressing the challenges posed by the rapid pace of FDA approvals and ensuring that patients have access to the most appropriate and effective therapies.

References

• [1] https://hmacademy.com/blog/oncology-conferences-in-2026-guide
• [2] https://hmacademy.com/blog/pharmacy-conferences-2026-healthcare-leaders-guide
• [3] https://faculty.mdanderson.org/profiles/alexandre_reuben.html